Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 7/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 7/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.46 |
| ▸ | PIP5K1C | O60331 | 3/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9537013 | 0.75 | MEN1 (0.46) | MAPTALDH1A1TSHRKDM4ECASP1 | |
| SCHEMBL137507 | 0.74 | PDK1 (0.58) | PI4KAPI4KBPIK3CDPIK3CGPIP5K1C | |
| SCHEMBL29504546 | 0.74 | PDK1 (0.58) | PI4KAPI4KBPIK3CDPIK3CGPIP5K1C | |
| Hydrochloric Acid SCHEMBL31194795 | 0.73 | PDK1 (0.56) | PI4KAPI4KBPIK3CDPIK3CGPIP5K1C | |
| SCHEMBL483604 | 0.72 | RIPK1 (0.38) | MAPTALDH1A1TP53HTTHSD17B10 | |
| SCHEMBL30319909 | 0.71 | PI4KA (0.46) | PI4KAPI4KBPIK3CDPIK3CGPIP5K1C | |
| SCHEMBL1851678 | 0.71 | PI4KA (0.46) | PI4KAPI4KBPIK3CDPIK3CGPIP5K1C | |
| SCHEMBL20272946 | 0.70 | ALDH1A1 (0.44) | MAPTALDH1A1TP53HTTHSD17B10 | |
| SCHEMBL832575 | 0.69 | ALDH1A1 (0.48) | MAPTALDH1A1TP53HTTHSD17B10 | |
| SCHEMBL29384237 | 0.69 | ALDH1A1 (0.48) | MAPTALDH1A1TP53HTTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 415 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218521-A1 | IMMUNOMODULATING TREATMENTS OF BODY CAVITIES | UROGEN PHARMA LTD. (IL) | 2023-07-13 | — | — | US | claimed |
| US-20200397695-A1 | IMMUNOMODULATING TREATMENTS OF BODY CAVITIES | UROGEN PHARMA LTD. (IL) | 2020-12-24 | — | — | US | claimed |
| US-10472420-B2 | Immune response modifier conjugates | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2019-11-12 | — | — | US | claimed |
| EP-3532505-A1 | IMMUNOMODULATING TREATMENTS OF BODY CAVITIES | Urogen Pharma Ltd. (IL) | 2019-09-04 | — | — | EP | claimed |
| US-20190201334-A1 | IMMUNOMODULATING TREATMENTS OF BODY CAVITIES | UROGEN PHARMA LTD. (IL) | 2019-07-04 | — | — | US | claimed |
| US-20190083592-A1 | IMMUNOSTIMULATORY COMBINATIONS | DARTMOUTH COLLEGE (US) | 2019-03-21 | — | — | US | claimed |
| WO-2018078620-A1 | IMMUNOMODULATING TREATMENTS OF BODY CAVITIES | UROGEN PHARMA LTD. (IL) | 2018-05-03 | — | — | WO | claimed |
| US-20160129095-A1 | Immunostimulatory Combinations | DARTMOUTH COLLEGE (US) | 2016-05-12 | — | — | US | claimed |
| US-20150141877-A1 | LED AND SHOCKWAVE THERAPY FOR TATTOO REMOVAL | INREXREM INC. (US) | 2015-05-21 | — | — | US | claimed |
| US-20150141625-A1 | IMMUNE RESPONSE MODIFIER CONJUGATES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2015-05-21 | — | — | US | claimed |
| US-20040141950-A1 | Immunostimulatory combinations | 3M INNOVATIVE PROPERTIES COMPANY | 2004-07-22 | — | — | US | claimed |
| WO-2004060319-A2 | IMMUNOSTIMULATORY COMBINATIONS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-07-22 | — | — | WO | claimed |
| US-20040091491-A1 | Immunostimulatory compositions and methods of stimulating an immune response | 3M INNOVATIVE PROPERTIES COMPANY | 2004-05-13 | — | — | US | claimed |
| WO-2004032829-A2 | IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF STIMULATING AN IMMUNE RESPONSE | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-04-22 | — | — | WO | claimed |
| US-20040014779-A1 | Methods and compositions related to IRM compounds and toll-like recptor pathways | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-22 | — | — | US | claimed |
| US-20030199538-A1 | Pharmaceutical formulation comprising an immune response modifier | 3M INNOVATIVE PROPERTIES COMPANY | 2003-10-23 | — | — | US | claimed |
| WO-2003072026-A2 | METHOD OF REDUCING AND TREATING UVB-INDUCED IMMUNOSUPPRESSION | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-09-04 | — | — | WO | claimed |
| US-20030161797-A1 | Method of reducing and treating UVB-induced immunosuppression | 3M INNOVATIVE PROPERTIES COMPANY | 2003-08-28 | — | — | US | claimed |
| WO-2003045391-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING AN IMMUNE RESPONSE MODIFIER | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-06-05 | — | — | WO | claimed |
| WO-2003043572-A2 | METHODS AND COMPOSITIONS RELATED TO IRM COMPOUNDS AND TOLL-LIKE RECEPTOR PATHWAYS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-05-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040091491-A1 | Immunostimulatory compositions and methods of stimulating an immune response | IFNG, MYD88, ICOS | PI4KA 4229/4885PI4KB 3583/4885PIK3CD 1930/4885 |
| US-20230218521-A1 | IMMUNOMODULATING TREATMENTS OF BODY CAVITIES | IL2, CD47, IFNG | PI4KA 3107/4885PI4KB 2235/4885PIK3CD 3832/4885 |
| US-20150141625-A1 | IMMUNE RESPONSE MODIFIER CONJUGATES | IFNG, CD74, MYD88 | PI4KA 3737/4885PI4KB 2893/4885PIK3CD 4548/4885 |
| US-20030199538-A1 | Pharmaceutical formulation comprising an immune response modifier | ICOS, STAT6, INMT | PI4KA 634/4885PI4KB 764/4885PIK3CD 736/4885 |
| US-20190201334-A1 | IMMUNOMODULATING TREATMENTS OF BODY CAVITIES | IL2, CD47, IFNG | PI4KA 3107/4885PI4KB 2235/4885PIK3CD 3832/4885 |
| US-20200397695-A1 | IMMUNOMODULATING TREATMENTS OF BODY CAVITIES | IL2, CD47, IFNG | PI4KA 3107/4885PI4KB 2235/4885PIK3CD 3832/4885 |
| US-20040014779-A1 | Methods and compositions related to IRM compounds and toll-like recptor pathways | TLR4, TLR3, TLR6 | PI4KA 870/4885PI4KB 382/4885PIK3CD 721/4885 |
| US-10472420-B2 | Immune response modifier conjugates | IFNG, CD74, MYD88 | PI4KA 3737/4885PI4KB 2893/4885PIK3CD 4548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.